Insulin delivery company Insulet Corporation NASDAQ:PODD will be reporting earnings this Wednesday morning. Here’s what you need to know.Insulet beat analysts’ revenue expectations last quarter, reporting revenues of $761.7 million, up 33.9% year on year. It was a very strong quarter for the compan…
Insulet's SEC Filings Touted Quality Assurance Inspections "At Various Steps in the Manufacturing Cycle" While Defective Controls at Its Acton Facility Allegedly Produced 7 Million Flawed PodsNEW YORK, July 23, 2026 /PRNewswire/ -- SueWallSt examines the adequacy of Insulet Corporation's (NASDAQ:PO…
Notice to Pension Funds, Asset Managers, and Fiduciaries Holding PODD: Institutional Portfolios Face Significant Exposure Following Two Omnipod Medical Device Corrections and Over $90 Per Share Decline from Pre-Disclosure LevelsNEW YORK, July 9, 2026 /PRNewswire/ -- Institutional investors holding…
Insulet PODD is well poised for growth in the upcoming quarters, owing to its strong momentum for the Omnipod 5 automated insulin delivery (AID) system for both Type 1 and Type 2 populations. The company is strongly executing against its long-term priorities to drive penetration, deepen competitive…
